Studies on the use of thyroid hormone and a thyroid hormone analogue in the treatment of congestive heart failure

Eugene Morkin, Gregory D. Pennock, Thomas E. Raya, Joseph J. Bahl, Steven Goldman

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

In heart failure, cardiac output is insufficient to meet the needs of the body for oxygen delivery. Available data suggest that alterations in thyroid hormone metabolism may contribute to defective myocardial performance. Accordingly, thyroid hormone or a thyroid hormone analogue that improves cardiac performance might be useful in the treatment of heart failure and has been studied. Experimental and theoretical results of these studies are reviewed and indicate that thyroid hormone increases cardiac output by a combination of effects on the heart and peripheral circulation, specifically by increasing myocardial contractile performance and decreasing venous compliance. In the rat postinfarction model of heart failure, treatment with low doses of thyroxine (1.5 μg/100 g) for 3 days produced a positive inotropic response, including an increase in rate of change of left ventricular pressure and a decrease in left ventricular end-diastolic pressure. These changes could be attributed to conversion to triiodothyronine, the active intracellular form of thyroid hormone. When treatment with thyroxine was continued at the same or higher doses (3 to 15 μg/100 g) for 10 to 12 days, heart rate increased and improvement in left ventricular end-diastolic pressure was not sustained. More favorable results were obtained with 3,5-diiodothyropropionic acid, a cardiotonic thyroid hormone analogue administered at doses of 375 μg/100 g, given in combination with captopril. Thus, triiodothyronine or a thyroid hormone analogue may be a useful adjunct to other measures in the treatment of heart failure.

Original languageEnglish (US)
JournalAnnals of Thoracic Surgery
Volume56
Issue number1 SUPPL.
DOIs
StatePublished - 1993

Fingerprint

Thyroid Hormones
Heart Failure
Triiodothyronine
Treatment Failure
Thyroxine
Cardiac Output
Blood Pressure
Cardiotonic Agents
Captopril
Ventricular Pressure
Compliance
Theoretical Models
Heart Rate
Oxygen

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Surgery

Cite this

Studies on the use of thyroid hormone and a thyroid hormone analogue in the treatment of congestive heart failure. / Morkin, Eugene; Pennock, Gregory D.; Raya, Thomas E.; Bahl, Joseph J.; Goldman, Steven.

In: Annals of Thoracic Surgery, Vol. 56, No. 1 SUPPL., 1993.

Research output: Contribution to journalArticle

Morkin, Eugene ; Pennock, Gregory D. ; Raya, Thomas E. ; Bahl, Joseph J. ; Goldman, Steven. / Studies on the use of thyroid hormone and a thyroid hormone analogue in the treatment of congestive heart failure. In: Annals of Thoracic Surgery. 1993 ; Vol. 56, No. 1 SUPPL.
@article{3c27f55e279f4a8ca790bf0297f6cbcb,
title = "Studies on the use of thyroid hormone and a thyroid hormone analogue in the treatment of congestive heart failure",
abstract = "In heart failure, cardiac output is insufficient to meet the needs of the body for oxygen delivery. Available data suggest that alterations in thyroid hormone metabolism may contribute to defective myocardial performance. Accordingly, thyroid hormone or a thyroid hormone analogue that improves cardiac performance might be useful in the treatment of heart failure and has been studied. Experimental and theoretical results of these studies are reviewed and indicate that thyroid hormone increases cardiac output by a combination of effects on the heart and peripheral circulation, specifically by increasing myocardial contractile performance and decreasing venous compliance. In the rat postinfarction model of heart failure, treatment with low doses of thyroxine (1.5 μg/100 g) for 3 days produced a positive inotropic response, including an increase in rate of change of left ventricular pressure and a decrease in left ventricular end-diastolic pressure. These changes could be attributed to conversion to triiodothyronine, the active intracellular form of thyroid hormone. When treatment with thyroxine was continued at the same or higher doses (3 to 15 μg/100 g) for 10 to 12 days, heart rate increased and improvement in left ventricular end-diastolic pressure was not sustained. More favorable results were obtained with 3,5-diiodothyropropionic acid, a cardiotonic thyroid hormone analogue administered at doses of 375 μg/100 g, given in combination with captopril. Thus, triiodothyronine or a thyroid hormone analogue may be a useful adjunct to other measures in the treatment of heart failure.",
author = "Eugene Morkin and Pennock, {Gregory D.} and Raya, {Thomas E.} and Bahl, {Joseph J.} and Steven Goldman",
year = "1993",
doi = "10.1016/0003-4975(93)90555-V",
language = "English (US)",
volume = "56",
journal = "Annals of Thoracic Surgery",
issn = "0003-4975",
publisher = "Elsevier USA",
number = "1 SUPPL.",

}

TY - JOUR

T1 - Studies on the use of thyroid hormone and a thyroid hormone analogue in the treatment of congestive heart failure

AU - Morkin, Eugene

AU - Pennock, Gregory D.

AU - Raya, Thomas E.

AU - Bahl, Joseph J.

AU - Goldman, Steven

PY - 1993

Y1 - 1993

N2 - In heart failure, cardiac output is insufficient to meet the needs of the body for oxygen delivery. Available data suggest that alterations in thyroid hormone metabolism may contribute to defective myocardial performance. Accordingly, thyroid hormone or a thyroid hormone analogue that improves cardiac performance might be useful in the treatment of heart failure and has been studied. Experimental and theoretical results of these studies are reviewed and indicate that thyroid hormone increases cardiac output by a combination of effects on the heart and peripheral circulation, specifically by increasing myocardial contractile performance and decreasing venous compliance. In the rat postinfarction model of heart failure, treatment with low doses of thyroxine (1.5 μg/100 g) for 3 days produced a positive inotropic response, including an increase in rate of change of left ventricular pressure and a decrease in left ventricular end-diastolic pressure. These changes could be attributed to conversion to triiodothyronine, the active intracellular form of thyroid hormone. When treatment with thyroxine was continued at the same or higher doses (3 to 15 μg/100 g) for 10 to 12 days, heart rate increased and improvement in left ventricular end-diastolic pressure was not sustained. More favorable results were obtained with 3,5-diiodothyropropionic acid, a cardiotonic thyroid hormone analogue administered at doses of 375 μg/100 g, given in combination with captopril. Thus, triiodothyronine or a thyroid hormone analogue may be a useful adjunct to other measures in the treatment of heart failure.

AB - In heart failure, cardiac output is insufficient to meet the needs of the body for oxygen delivery. Available data suggest that alterations in thyroid hormone metabolism may contribute to defective myocardial performance. Accordingly, thyroid hormone or a thyroid hormone analogue that improves cardiac performance might be useful in the treatment of heart failure and has been studied. Experimental and theoretical results of these studies are reviewed and indicate that thyroid hormone increases cardiac output by a combination of effects on the heart and peripheral circulation, specifically by increasing myocardial contractile performance and decreasing venous compliance. In the rat postinfarction model of heart failure, treatment with low doses of thyroxine (1.5 μg/100 g) for 3 days produced a positive inotropic response, including an increase in rate of change of left ventricular pressure and a decrease in left ventricular end-diastolic pressure. These changes could be attributed to conversion to triiodothyronine, the active intracellular form of thyroid hormone. When treatment with thyroxine was continued at the same or higher doses (3 to 15 μg/100 g) for 10 to 12 days, heart rate increased and improvement in left ventricular end-diastolic pressure was not sustained. More favorable results were obtained with 3,5-diiodothyropropionic acid, a cardiotonic thyroid hormone analogue administered at doses of 375 μg/100 g, given in combination with captopril. Thus, triiodothyronine or a thyroid hormone analogue may be a useful adjunct to other measures in the treatment of heart failure.

UR - http://www.scopus.com/inward/record.url?scp=0027317811&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027317811&partnerID=8YFLogxK

U2 - 10.1016/0003-4975(93)90555-V

DO - 10.1016/0003-4975(93)90555-V

M3 - Article

VL - 56

JO - Annals of Thoracic Surgery

JF - Annals of Thoracic Surgery

SN - 0003-4975

IS - 1 SUPPL.

ER -